Stock Ratings / Health Care / SRPT / insiders

GENB (61) ZYME (47) SLS (35) TRVI (39) ⌘ Pro Terminal →

Sarepta Therapeutics Inc. (SRPT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$19.23 -0.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.18

Sarepta Therapeutics Inc. (SRPT) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.03B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $19.18 (-0.27%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRPT)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY SRPT SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 51.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±11% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$17.85-4.2% Next Q

Q2 (-2Q)

Grade E$17.10+3.7% Next Q

Q3 (-1Q)

Grade E$17.73+8.5% Next Q

Current

Grade D-$19.23-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRPT currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.24) and Max Pain ($20.19) forces dealer call-delta covering toward $25.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SRPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SRPT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SRPT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SRPT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRPT)

✓Walkthrough of SRPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.90%▲ ASCENDING CHANNEL

2026-10-30O $19.04H $19.50L $18.41C $19.23VOL 1.32M

RES: $26.50SUP: $16.75SMA50: $19.24SMA200: $18.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRPT Butterfly Map → + Track SRPT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SRPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRPT)

Health Care Rank #813 of 1016 ⚔️ GENB vs SRPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRPT vs. GENB, ZYME, SLS, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sarepta Therapeutics Inc. (SRPT) ranks #813 by composite RQD confidence (35/100, grade D-) and #261 by equity capitalization ($2.03B). Within this direct 5-issuer industry benchmark cohort, SRPT leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with SRPT at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRPT ACTIVE Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-0.47%	$2.03B	Benchmark Subject
GENB Generate Biomedicines Inc.	C-	61/100	—	—	—	+2.54%	$2.02B	/genb-vs-srpt →
ZYME Zymeworks Inc.	D	47/100	—	—	-32.2%	-0.66%	$2.02B	/zyme-vs-srpt →
SLS SELLAS Life Sciences Group Inc.	D-	35/100	—	—	-21.8%	-2.17%	$2.05B	/sls-vs-srpt →
TRVI Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-srpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000873303

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported GAAP revenue of $1.86B (+4.3% vs. FY2024 revenue of $1.79B , and +62.8% cumulative change since FY2023) , GAAP net income of -$713.4M, operating cash flow of -$205.5M, and free cash flow of -$307.5M (+10.3% YoY). On the balance sheet, SRPT closed FY2025 with $3.35B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.86B	-$713.4M	-$205.5M	-$307.5M	$3.35B	—
FY2024 (FY)	2024-12-31	$1.79B	$235.2M	-$205.8M	-$342.7M	$3.96B	—
FY2023 (FY)	2023-12-31	$1.14B	-$536.0M	-$501.0M	-$501.0M	—	—

3. SRPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $19.23 (-0.47% 1D, market cap $2.03B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRPT ranks #813 in composite RQD confidence.

How does SRPT compare to GENB and ZYME in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, GENB (Generate Biomedicines Inc.) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.02B) and ZYME (Zymeworks Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRPT?

Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?

SRPT last traded at $19.23 (-0.47% on volume of 1,188,156 shares), positioning the stock -0.05% below its 50-day simple moving average ($19.24) and +2.72% above its 200-day simple moving average ($18.72). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 45.5% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($17.11 to $21.35).

SRPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SRPT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SRPT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: SRPT RQD Cockpit SRPT 12M Forecast SRPT Earnings & Move SRPT Dividends & DRIP SRPT Insiders & 13F SRPT Whale Options SRPT Profit Sankey SRPT News & Why